Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | XOMA |
---|---|---|
09:32 ET | 255 | 30.6 |
09:39 ET | 300 | 30.4854 |
09:50 ET | 2052 | 30.9504 |
10:02 ET | 289 | 30.44 |
10:22 ET | 300 | 30.6 |
10:33 ET | 100 | 30.7 |
10:44 ET | 600 | 30.85 |
10:47 ET | 100 | 30.7 |
11:23 ET | 100 | 30.7 |
11:25 ET | 100 | 30.55 |
11:27 ET | 100 | 30.575 |
11:30 ET | 500 | 30.5 |
11:38 ET | 100 | 30.5 |
11:48 ET | 100 | 30.5 |
12:10 ET | 100 | 30.5 |
12:19 ET | 100 | 30.5 |
01:06 ET | 600 | 30.6 |
01:15 ET | 600 | 30.7 |
01:18 ET | 200 | 30.7 |
01:20 ET | 100 | 30.595 |
01:31 ET | 100 | 30.7 |
01:54 ET | 200 | 30.7 |
02:02 ET | 200 | 30.73 |
02:03 ET | 100 | 30.735 |
02:23 ET | 100 | 30.6957 |
03:12 ET | 525 | 30.61 |
03:14 ET | 338 | 30.675 |
03:15 ET | 100 | 30.555 |
03:17 ET | 18925 | 30.85 |
03:19 ET | 664 | 30.85 |
03:24 ET | 800 | 30.53 |
03:30 ET | 600 | 30.7 |
03:35 ET | 100 | 30.66 |
03:42 ET | 200 | 30.7 |
03:46 ET | 200 | 30.57 |
03:51 ET | 100 | 30.55 |
04:00 ET | 5907 | 31.06 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
XOMA Royalty Corp | 355.8M | -10.1x | --- |
Northwest Biotherapeutics Inc | 352.3M | -4.2x | --- |
enGene Holdings Inc | 339.6M | -1.7x | --- |
Jasper Therapeutics Inc | 330.8M | -4.8x | --- |
Prime Medicine Inc | 384.1M | -1.6x | --- |
Kodiak Sciences Inc | 325.7M | -1.8x | --- |
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's royalty portfolio includes OJEMDA (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, mezagitamab (TAK-079), acimtamig (AFM13), AB054, ficlatuzumab (AV-299), COM902, vosaroxin, aldoxorubicin, INCAGN02385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], CMP-001 (vidutolimod), NTM-1631, NTM-1634, NTM-1633, NTM-1632, NIR178, MK-4830, AFM24, INCAGN01949, AB101, and CFZ533 (iscalimab).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $355.8M |
---|---|
Revenue (TTM) | $21.6M |
Shares Outstanding | 11.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.86 |
EPS | $-3.06 |
Book Value | $7.72 |
P/E Ratio | -10.1x |
Price/Sales (TTM) | 16.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -154.31% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.